Date: 2011-06-08
Type of information:
Compound: isletOrganDOT™
Company: Asterand (UK) Capsant Neurotechnologies (UK)
Therapeutic area: Metabolic diseases
Type agreement: Licensing
Action mechanism: 3-D cell based assay platform for evaluating therapeutic compounds for diabetes
Disease: Diabetes
Details: Asterand, a leading provider of human tissue and cell-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, has announced the exclusive licensing on a worldwide basis from Capsant Neurotechnologies Ltd. and the introduction of isletOrganDOT™, a novel 3-D cell based assay platform for evaluating therapeutic compounds for diabetes. This new service is a 3D tissue culture system that can replicate, under physiological and pharmacological control, the release of mediators from human islet cells. The platform supports human reconstituted primary islets in a manner that allows cells to retain functionality for up to 14 days in culture. This feature permits carefully timed and repeat dosing regimes for test compounds. In addition, the 24-insert plate format and the ability to run multiple plates within a single study offers our clients numerous options for testing batches of early hit compounds through to in-depth profiling of lead/pre-clinical compounds.
Financial terms: Financial details were not disclosed.
Latest news:
